JingSi Jiang, XiaoGang Li, YuXin Mi, YiYing Wang, YanXi Heng, ZhiWen Li, Min Deng
{"title":"利鲁唑对中国ALS队列中生存和ALSFRS变化的真实证据。","authors":"JingSi Jiang, XiaoGang Li, YuXin Mi, YiYing Wang, YanXi Heng, ZhiWen Li, Min Deng","doi":"10.1080/17582024.2025.2488235","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to evaluate the effects of riluzole on survival and changes in ALS Functional Rating Scale (ALSFRS) among Chinese patients with Amyotrophic Lateral Sclerosis (ALS).</p><p><strong>Patients & methods: </strong>Propensity score matching was used to balance baseline variables between the riluzole group (<i>n</i> = 238) and control group (<i>n</i> = 454). Survival was analyzed using Kaplan - Meier curves and Cox regression, while multivariable linear regression assessed ALSFRS changes at 6 and 12 months. Subgroup analyses were conducted to identify potential responders.</p><p><strong>Results: </strong>Riluzole did not significantly improve survival (<i>p</i> = 0.478) or ALSFRS changes at 6 months (<i>p</i> = 0.380) or 12 months (<i>p</i> = 0.175). Subgroup analyses revealed no survival benefit in any subgroup, and further stratification showed inconsistent adverse effects on ALSFRS scores.</p><p><strong>Conclusions: </strong>Riluzole neither prolonged survival nor slowed functional decline in Chinese ALS patients, with no subgroup demonstrating a better response.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"77-87"},"PeriodicalIF":2.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12118432/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort.\",\"authors\":\"JingSi Jiang, XiaoGang Li, YuXin Mi, YiYing Wang, YanXi Heng, ZhiWen Li, Min Deng\",\"doi\":\"10.1080/17582024.2025.2488235\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>This study aimed to evaluate the effects of riluzole on survival and changes in ALS Functional Rating Scale (ALSFRS) among Chinese patients with Amyotrophic Lateral Sclerosis (ALS).</p><p><strong>Patients & methods: </strong>Propensity score matching was used to balance baseline variables between the riluzole group (<i>n</i> = 238) and control group (<i>n</i> = 454). Survival was analyzed using Kaplan - Meier curves and Cox regression, while multivariable linear regression assessed ALSFRS changes at 6 and 12 months. Subgroup analyses were conducted to identify potential responders.</p><p><strong>Results: </strong>Riluzole did not significantly improve survival (<i>p</i> = 0.478) or ALSFRS changes at 6 months (<i>p</i> = 0.380) or 12 months (<i>p</i> = 0.175). Subgroup analyses revealed no survival benefit in any subgroup, and further stratification showed inconsistent adverse effects on ALSFRS scores.</p><p><strong>Conclusions: </strong>Riluzole neither prolonged survival nor slowed functional decline in Chinese ALS patients, with no subgroup demonstrating a better response.</p>\",\"PeriodicalId\":19114,\"journal\":{\"name\":\"Neurodegenerative disease management\",\"volume\":\" \",\"pages\":\"77-87\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12118432/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurodegenerative disease management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17582024.2025.2488235\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17582024.2025.2488235","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort.
Aims: This study aimed to evaluate the effects of riluzole on survival and changes in ALS Functional Rating Scale (ALSFRS) among Chinese patients with Amyotrophic Lateral Sclerosis (ALS).
Patients & methods: Propensity score matching was used to balance baseline variables between the riluzole group (n = 238) and control group (n = 454). Survival was analyzed using Kaplan - Meier curves and Cox regression, while multivariable linear regression assessed ALSFRS changes at 6 and 12 months. Subgroup analyses were conducted to identify potential responders.
Results: Riluzole did not significantly improve survival (p = 0.478) or ALSFRS changes at 6 months (p = 0.380) or 12 months (p = 0.175). Subgroup analyses revealed no survival benefit in any subgroup, and further stratification showed inconsistent adverse effects on ALSFRS scores.
Conclusions: Riluzole neither prolonged survival nor slowed functional decline in Chinese ALS patients, with no subgroup demonstrating a better response.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
